Article
Oncology
Ming-Ying Lu, Ta-Wei Liu, Po-Cheng Liang, Ching- Huang, Yi-Shan Tsai, Pei-Chien Tsai, Yu-Min Ko, Wen-Hsuan Wang, Ching-Chih Lin, Kuan-Yu Chen, Shu-Chi Wang, Yu-Ju Wei, Po-Yao Hsu, Tyng-Yuan Jang, Ming-Yen Hsieh, Chih-Wen Wang, Ming-Lun Yeh, Zu-Yau Lin, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Summary: This study established a machine learning-based HCC model using artificial intelligence to predict the occurrence of HCC by integrating clinical features and genetic biomarkers. The results showed that changes in gene expression before and after treatment were significantly correlated with HCC development. A gene score derived from a decision tree algorithm could accurately identify HCC, and a prediction model combining the gene score and fibrosis-4 index had high accuracy in predicting HCC probability.
AMERICAN JOURNAL OF CANCER RESEARCH
(2023)
Article
Oncology
Ming-Ying Lu, Ta-Wei Liu, Po-Cheng Liang, Ching- Huang, Yi-Shan Tsai, Yu-Min Ko, Pei-Chien Tsai, Wen-Hsuan Wang, Ching-Chih Lin, Kuan-Yu Chen, Shu-Chi Wang, Yu-Ju Wei, Po-Yao Hsu, Tyng-Yuan Jang, Ming -Yen Hsieh, Chih-Wen Wang, Ming-Lun Yeh, Zu-Yau Lin, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Summary: This study developed a machine learning-based model to predict the risk of hepatocellular carcinoma (HCC) in patients after successful eradication of the hepatitis C virus. The study found that changes in the expression of specific genes were significantly associated with HCC development. This research provides valuable insights for personalized HCC surveillance.
AMERICAN JOURNAL OF CANCER RESEARCH
(2023)
Article
Gastroenterology & Hepatology
Ming-Ying Lu, Ming-Lun Yeh, Ching- Huang, Shu-Chi Wang, Yi-Shan Tsai, Pei-Chien Tsai, Yu-Min Ko, Ching-Chih Lin, Kuan-Yu Chen, Yu-Ju Wei, Po-Yao Hsu, Cheng-Ting Hsu, Tyng-Yuan Jang, Ta-Wei Liu, Po-Cheng Liang, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Summary: Chronic hepatitis C virus (HCV) infection induces changes in cytokine expression, and this study found that downregulation of TNF-alpha significantly increases the risk of hepatocellular carcinoma (HCC) after successful antiviral therapy.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Peter P. Mueller, Qiushi Chen, Turgay Ayer, Gizem S. Nemutlu, Ali Hajjar, Emily D. Bethea, Mary Linton B. Peters, Brian P. Lee, Naveed Z. Janjua, Fasiha Kanwal, Jagpreet Chhatwal
Summary: This study evaluated the cost-effectiveness of biannual surveillance for hepatocellular carcinoma (HCC) in patients cured of hepatitis C. The findings suggest that biannual surveillance is cost-effective until the age of 70 for patients with cirrhosis, and until the age of 60 for patients with stable advanced fibrosis.
JOURNAL OF HEPATOLOGY
(2022)
Article
Oncology
Yuan-Hung Kuo, Tzu-Hsin Huang, Jing-Houng Wang, Yen-Yang Chen, Ming-Chao Tsai, Yen-Hao Chen, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, Chao-Hung Hung
Summary: This study confirms that while HCV-HCC patients may have a better prognosis when using sorafenib, there is no difference in prognosis between HBV-HCC and HCV-HCC patients when it comes to controlling viral load. The control of viral load is associated with prognosis, while HBV or HCV infection is not.
Review
Microbiology
Natsumi Oe, Haruhiko Takeda, Yuji Eso, Atsushi Takai, Hiroyuki Marusawa
Summary: This article reviews the development of HCC after HCV eradication and discusses the current understanding of the molecular mechanisms of tumorigenesis after virus elimination, focusing on the genetic and epigenetic background of chronically damaged liver tissues.
Review
Oncology
Xinhe Zhang, Lin Guan, Haoyu Tian, Zilu Zeng, Jiayu Chen, Die Huang, Ji Sun, Jiaqi Guo, Huipeng Cui, Yiling Li
Summary: HCC is a common cancer with increasing incidence caused by HBV and HCV infections, liver cirrhosis, and metabolic risk factors. Predictive factors can assess the risk of HCC, and prevention strategies include vaccination, antiviral treatment, and HCC management to reduce recurrence.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Henrique A. Lima, Yutaka Endo, Zorays Moazzam, Laura Alaimo, Chanza Shaikh, Muhammad M. Munir, Vivian Resende, Alfredo Guglielmi, Hugo P. Marques, Francois Cauchy, Vincent Lam, George A. Poultsides, Irinel Popescu, Sorin Alexandrescu, Guillaume Martel, Itaru Endo, Minoru Kitago, Feng Shen, Timothy M. Pawlik
Summary: In hepatocellular carcinoma treatment, heterogeneity still exists within the Barcelona clinic liver cancer subcategories. A simple model was developed to better discriminate and predict prognosis after resection. This model consistently outperformed the existing BCLC model in terms of discrimination power and prognostication.
JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Tatsuya Minami, Masaya Sato, Hidenori Toyoda, Satoshi Yasuda, Tomoharu Yamada, Takuma Nakatsuka, Kenichiro Enooku, Hayato Nakagawa, Hidetaka Fujinaga, Masashi Izumiya, Yasuo Tanaka, Motoyuki Otsuka, Takamasa Ohki, Masahiro Arai, Yoshinari Asaoka, Atsushi Tanaka, Kiyomi Yasuda, Hideaki Miura, Itsuro Ogata, Toshiro Kamoshida, Kazuaki Inoue, Ryo Nakagomi, Masatoshi Akamatsu, Hiroshi Mitsui, Hajime Fujie, Keiji Ogura, Koji Uchino, Hideo Yoshida, Kazuyuki Hanajiri, Tomonori Wada, Kiyohiko Kurai, Hisato Maekawa, Yuji Kondo, Shuntaro Obi, Takuma Teratani, Naohiko Masaki, Kayo Nagashima, Takashi Ishikawa, Naoya Kato, Hiroshi Yotsuyanagi, Kyoji Moriya, Takashi Kumada, Mitsuhiro Fujishiro, Kazuhiko Koike, Ryosuke Tateishi
Summary: A machine learning model has been developed to predict the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C after achieving a sustained virologic response (SVR). The model showed good discriminative ability in external validation and can generate individualized predictive curves for each patient using an online application.
JOURNAL OF HEPATOLOGY
(2023)
Article
Virology
Leona Radmanic, Kristian Bodulic, Petra Simicic, Adriana Vince, Snjezana Zidovec Lepej
Summary: This study evaluated the effect of DAA treatment on serum cytokine and growth factor profiles in patients with chronic hepatitis C. The results showed that DAA treatment can inhibit inflammatory processes and promote liver regeneration.
Article
Oncology
Marco Y. W. Zaki, Ahmed M. Fathi, Samara Samir, Nardeen Eldafashi, Kerolis Y. William, Maiiada Hassan Nazmy, Moustafa Fathy, Upkar S. Gill, Shishir Shetty
Summary: HBV and HCV infections are the most common risk factors for hepatocellular carcinoma (HCC), and their distribution affects the global prevalence of this type of liver cancer. Hepatitis infections elicit immune responses within the liver microenvironment, and persistent viral infection leads to chronic liver inflammation and carcinogenesis.
Article
Virology
Azusa Ohta, Eiichi Ogawa, Masayuki Murata, Yuji Matsumoto, Sho Yamasaki, Hiroaki Ikezaki, Norihiro Furusyo
Summary: The study aimed to assess the association between host genetic factors and de novo HCC after achieving sustained virological response (SVR) in CHC patients. The PNPLA3 genotype was independently associated with the development of de novo HCC in CHC patients who achieved SVR.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Gastroenterology & Hepatology
Maria M. Zanone, Claudia Marinucci, Alessia Ciancio, Dario Cocito, Federica Zardo, Emanuela Spagone, Bruno Ferrero, Cristina Cerruti, Lorena Charrier, Franco Cavallo, Giorgio M. Saracco, Massimo Porta
Summary: This longitudinal study assessed the prevalence and outcome of neuropathy in chronic HCV patients before and after DAA treatment. Results showed improvement in neuropathy after DAA therapy, supporting the need for larger intervention studies.
LIVER INTERNATIONAL
(2021)
Review
Immunology
Zelin Tian, Chen Xu, Peijun Yang, Zhibin Lin, Wenlong Wu, Wenjie Zhang, Jian Ding, Rui Ding, Xuan Zhang, Kefeng Dou
Summary: Hepatocellular carcinoma (HCC), caused by viral hepatitis, alcoholic, and non-alcoholic fatty liver disease (NAFLD), is the sixth most common cancer worldwide. Viral hepatitis accounts for 80% of HCC cases globally. NAFLD has become the most common liver disease and major risk factor for HCC in developed countries. This review discusses the specific and similar pathogenesis mechanisms of viral hepatitis-induced HCC and NAFLD-induced HCC, including viral proteins, genetic factors, epigenetic modifications, and abnormal lipid metabolism.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Gastroenterology & Hepatology
Erwan Vo Quang, Yusuke Shimakawa, Pierre Nahon
Summary: Hepatitis B and C are prominent risk factors for hepatocellular carcinoma in different regions, with a goal to eliminate viral hepatitis globally by 2030. Measures like vaccination, antiviral therapies, and liver cancer screening programs are crucial in reducing the burden of HCC worldwide.
LIVER INTERNATIONAL
(2021)